Scholar Rock’s EU drug decision hits a delay

Another small delay, because biotech loves those

Scholar Rock said the European Union’s opinion on its experimental spinal muscular atrophy treatment could be pushed to later in 2026. Translation: the approval clock is still ticking, but it’s moving in slow motion again.

Why the pause matters

The holdup isn’t about a dramatic new safety scare or a sudden efficacy problem. It’s more bureaucratic, which is somehow both less exciting and more annoying: regulators are waiting for the U.S. FDA to classify a manufacturing facility that’s included in the company’s European filing.

That means the drug’s path in Europe is now tied to a separate regulatory box-checking process in the U.S. Biotech, as always, is a team sport played by people in different time zones wearing lab coats.

What investors should watch

For SRRK holders, this is mostly about timing and sentiment:

• A later opinion can push out the next potential catalyst
• Regulatory delays can make investors more cautious about commercial timelines
• Any update from the FDA on the manufacturing site could become the next big domino

Big picture: this doesn’t kill the story, but it does add a little more waiting to a process that was already moving at biotech speed — which is to say, not fast.